{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:30:38Z","timestamp":1788618638525,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of iGlarLixi with insulin glargine 100\u2009units\/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin\u2009with or without\u2009a second oral antihyperglycaemic drug (OAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      LixiLan\u2010O\u2010AP (NCT03798054) was a 24\u2010week multicentre study in adults (n\u00a0=\u00a0878, mean age 56.0\u2009years, mean body mass index 26.0\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) with glycated haemoglobin (HbA1c) levels \u226553 mmol\/mol (7%)\u00a0and \u226497 mmol\/mol (11%) on OAD(s), randomized (2:2:1) to open\u2010label once\u2010daily iGlarLixi, iGlar or Lixi while on continued metformin \u00b1 sodium\u2010glucose cotransporter\u20102 inhibitors. The primary efficacy endpoint was change in HbA1c.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 24\u2009weeks, greater reductions in HbA1c from baseline (67 mmol\/mol; 8.3%) were seen with iGlarLixi (\u221221 mmol\/mol; \u22121.9%) compared with iGlar (\u221216 mmol\/mol; \u22121.4%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.0001) and Lixi (\u221210 mmol\/mol; \u22120.9%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.0001). Greater proportions of participants achieved HbA1c &lt;53 mmol\/mol (&lt;7%) with iGlarLixi versus iGlar or Lixi (79%, 60% and 30%, respectively), overall and as composite endpoints including weight and hypoglycaemia. iGlarLixi improved 2\u2010hour postprandial glucose versus iGlar and Lixi and mitigated the weight gain seen with iGlar (least squares mean difference \u22121.1\u2009kg;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u20090.0001). Documented \u22643.9\u2009mmol\/L (\u226470\u2009mg\/dL) hypoglycaemia was similar between iGlarLixi and iGlar (both 3.38 events per participant\u2010year). The incidence rates of nausea and vomiting were lower with iGlarLixi (14% and 6%) than Lixi (21% and 11%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iGlarLixi achieved significant HbA1c reductions, to near\u2010normoglycaemic levels, compared with iGlar or Lixi, with no meaningful additional risk of hypoglycaemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi. iGlarLixi with specifically adapted ratios may provide an efficacious and well\u2010tolerated treatment option for Asian Pacific people with T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14722","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T23:43:23Z","timestamp":1650411803000},"page":"1522-1533","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety benefits of\n                    <scp>iGlarLixi<\/scp>\n                    versus insulin glargine 100\u2009U\/\n                    <scp>mL<\/scp>\n                    or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The\n                    <scp>LixiLan\u2010O\u2010AP<\/scp>\n                    randomized controlled trial"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-9404","authenticated-orcid":false,"given":"Wenying","family":"Yang","sequence":"first","affiliation":[{"name":"China\u2010Japan Friendship Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Dong","sequence":"additional","affiliation":[{"name":"Jinan Central Hospital  Jinan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingju","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Fourth Affiliated Hospital of Harbin Medical University  Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-6066","authenticated-orcid":false,"given":"Guoyue","family":"Yuan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Jiangsu University  Zhenjiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-4072","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital, School of Clinical Medicine Tsinghua University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Gu","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ping","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LixiLan\u2010O\u2010AP trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908292"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4172\/1747-0862.S1-008"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12293"},{"key":"e_1_2_9_8_1","first-page":"311","article-title":"Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition)","volume":"37","author":"Diabetes Branch of Chinese Medical Association","year":"2021","journal-title":"Chin J Endocrinol Metab"},{"key":"e_1_2_9_9_1","unstructured":"Sanofi.Soliqua\u00ae: US prescribing information.2019. Accessed June 2020.https:\/\/products.sanofi.us\/soliqua100-33\/soliqua100-33.pdf"},{"key":"e_1_2_9_10_1","unstructured":"Sanofi.Suliqua\u00ae: EU summary of product characteristics.2020. Accessed May 2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/suliqua"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1541790"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14036"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2452"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14005"},{"key":"e_1_2_9_18_1","first-page":"83","article-title":"Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults\u2014study on optimal cut\u2010off points of body mass index and waist circumference in Chinese adults","volume":"15","author":"Zhou BF","year":"2002","journal-title":"Biomed Environ Sci"},{"key":"e_1_2_9_19_1","article-title":"Characteristics of the pathophysiology of type 2 diabetes in Asians","volume":"2","author":"Cho YM","year":"2017","journal-title":"Ann Laparosc Endosc Surg"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0220"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13673"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14052"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1541316"},{"key":"e_1_2_9_24_1","first-page":"S332","article-title":"Dual I China: Improved glycaemic control with IDegLira versus its mono\u2010components in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drugs","volume":"63","author":"Wang W","year":"2020","journal-title":"Diabetologia"},{"key":"e_1_2_9_25_1","unstructured":"Novo N.Clinical trial report: a trial comparing the efficacy and safety of insulin degludec\/liraglutide insulin degludec and liraglutide in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs). DUAL I China.2020. Accessed 4 May 2022."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00783-4"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14154"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106821"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14722","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:36:36Z","timestamp":1761867396000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/dom.14722"],"URL":"https:\/\/doi.org\/10.1111\/dom.14722","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"2022-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}